Search Results
Your search for ,had matches 18604 pages
Showing 12001 - 12050SSO 2017: Preclinical Trial Shows Intratumoral Vaccination Induces Antitumor Response in Pancreatic Cancer
Building on their previous research focusing on intratumoral vaccination for the most common form of pancreatic cancer, investigators from Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School have shown that in a mouse model of early-stage resected pancreatic...
ASCO Addresses New Policies That Threaten Access to Opioids
Since the mid-2000s, medication and illicit drug abuse in the United Sates has steadily increased, creating what has now been termed an “opioid epidemic.” In response, Congress and the Bush and Obama Administrations have launched intervention and regulatory proposals to help turn the troubling...
For One Hematologist, No Disease Progressions in Follicular Lymphoma With Rituximab Maintenance
Patients with follicular lymphoma are clearly living longer without disease progression, but what clinician has had no patients progress? Michael Auerbach, MD, a hematologist/oncologist in private practice in Baltimore and Clinical Professor of Medicine at Georgetown University, may have these...
Plinabulin Improves Survival in Subset of Patients With Non–Small Cell Lung Cancer
The investigational small-molecule plinabulin yielded some interesting benefits when added to docetaxel in previously treated patients with stage III/IV non–small cell lung cancer (NSCLC), in a phase II study.1 Although the benefit of the doublet was modest in the overall study population, the...
Expert Point of View: Heather L. McArthur, MD, MPH
Study discussant Heather L. McArthur, MD, MPH, Medical Director of Breast Oncology at Cedars-Sinai Medical Center, Los Angeles, noted that human papillomavirus (HPV) vaccination has been shown to prevent HPV-related malignancies and eradicate high-grade, HPV16-positive premalignant lesions....
KEYNOTE Trial Data Suggest Features Predicting Response to Pembrolizumab
A high mutational load and the presence of a T-cell–“inflamed” environment may independently predict for treatment response to pembrolizumab (Keytruda) and progression-free survival, according to a study presented by Tanguy Seiwert, MD, of the University of Chicago, at the 2017 ASCO-SITC Clinical...
Expert Point of View: Joseph Greer, PhD
“These data are consistent with other studies we have conducted in advanced lung cancer, in which we similarly found that one-third of patients believed that their metastatic lung cancer was curable. These patients ostensibly already had conversations with their oncologists about their prognosis...
Aligning Patient Expectations With Treatment Goals in the Metastatic Setting
More than one-third of men with incurable metastatic prostate cancer mistakenly believe that their cancer may be curable, according to a survey of patient expectations at an academic cancer center. “This study is part of a larger survey of treatment decision-making among men with metastatic...
Developing Better Multidisciplinary Strategies
“More than any other disease, head and neck cancer requires constant interplay between a number of different specialties,” Sandeep Samant, MD, Chief, Head and Neck Surgery, Northwestern Medicine, and Chair of the Multidisciplinary Head & Neck Symposium sponsored by the Robert H. Lurie...
Making the Case for Sentinel Node Biopsy in Early Cancers of the Oral Cavity
“The majority of patients with oral cavity cancers will undergo an unnecessary operation,” Sandeep Samant, MD, stated at a session on managing N0 neck cancer at the 2016 Lurie Cancer Center Multidisciplinary Head & Neck Symposium in Chicago.1 That operation is elective neck dissection, and it ...
Online Symptom-Management Curriculum May Improve Depression and Fatigue in Breast Cancer Survivors
With thousands of devices to track and manage health and wellness, eHealth tools are beginning to transform modern health care and research, demonstrating quantifiable improvements in patient outcomes. According to the results of a randomized controlled trial (Reimagine), breast cancer survivors...
Search Continues for Effective Way to Prevent Lymphedema in Breast Cancer Survivors
There was no difference in the incidence of lymphedema at 18 months in breast cancer patients randomized to a physical therapy intervention with education materials compared with a control.1 Although poor adherence to the intervention may have been a factor, these results, described as “very...
Moderate Activity May Improve Overall and Progression-Free Survival in Patients With Metastatic Colorectal Cancer
Patients with metastatic colon cancer who exercise may live longer, according to an analysis of the CALGB/SWOG 80405 trial presented at the 2017 Gastrointestinal Cancers Symposium.1 According to the authors, this is the first study to demonstrate an association between physical activity and...
Expert Point of View: Nancy Baxter, MD, PhD & Steven H. Lin, MD, PhD
“CALGB 80803 really helps move the field forward,” said press briefing moderator and ASCO spokesperson Nancy Baxter, MD, PhD, a surgeon from St. Michael’s Hospital in Toronto, Ontario, Canada. “PET [positron-emission tomography] scans may prove to be a valuable tool to help oncologists fine-tune...
Early PET Imaging May Guide Treatment Decisions in Esophageal Cancer
In patients with resectable esophageal or gastroesophageal junction cancer, positron-emission tomography (PET) imaging was used to assess response to induction chemotherapy. PET nonresponders were identified after the first few cycles and were switched to an alternate regimen. This strategy greatly ...
Nivolumab Shows Benefit in Advanced Hepatocellular Carcinoma
In patients with advanced hepatocellular carcinoma, treatment with nivolumab (Opdivo) resulted in responses and long-term survival in patients who were either previously treated or naive to sorafenib (Nexavar), CheckMate 040 has shown.1 Altogether 19% of patients responded to the antibody...
Expert Point of View: Partow Kebriaei, MD
Partow Kebriaei, MD, Professor in the Department of Stem Cell Transplant and Cellular Therapy at The University of Texas MD Anderson Cancer Center, Houston, commented on the findings presented by Marty et al for The ASCO Post. “In this multicenter, randomized, placebo-controlled study, the use of...
New Antiviral Agent May Prevent Posttransplant Cytomegalovirus Infections
Patients receiving the antiviral letermovir (MK-8228, AIC246), as compared to placebo, were almost twice as likely to avoid infection with cytomegalovirus or fail for other reasons in a randomized phase III international trial presented at the 2017 BMT Tandem Meetings, the joint meeting of the...
Novel Immunotherapeutic Vaccine Studied in Colorectal Cancer
Patients with advanced colorectal cancer mounted a robust response to an experimental vaccine and low-dose cyclophosphamide, and strong responses were associated with improvements in survival in a phase I/II clinical trial of modified vaccinia virus Ankara–5T4 (TroVax).1 Martin Scurr, PhD, of...
Active Surveillance Appears to Be Safe for Small Renal Masses
The prospective Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry shows that over the intermediate term, active surveillance appears to be as safe as primary intervention for carefully selected, older, sicker patients with small renal masses.1 As the data mature,...
Pembrolizumab Affords Long-Term Survival to One-Fourth of Selected Patients With NSCLC, Alternative Statistical Model Suggests
Statistical modeling of long-term survival from the KEYNOTE trials of the programmed cell death protein 1 (PD-1)–inhibitor pembrolizumab (Keytruda) estimates that one-quarter of appropriately selected patients with advanced non–small cell lung cancer (NSCLC) may attain long-term survival.1 “In...
Multikinase Inhibitor Treatment Responses in Patients With RET-Rearranged NSCLC
In a report from the Global, Multicenter RET Registry in the Journal of Clinical Oncology, Gautschi et al documented response rates with multikinase RET inhibitors in patients with RET-rearranged non–small cell lung cancer (NSCLC). Study Details The study involved registry data (through...
Suboptimal BMD Evaluation in Postmenopausal Women With Early-Stage Breast Cancer Receiving Aromatase Inhibitors
In a study reported in the Journal of Oncology Practice, Stratton et al found that most postmenopausal Medicare patients with early-stage breast cancer receiving aromatase inhibitor therapy do not receive recommended bone mineral density (BMD) measurements. Most expert panels recommend BMD...
Adding Vandetanib to Gemcitabine in Locally Advanced or Metastatic Pancreatic Carcinoma
In a UK phase II trial reported in The Lancet Oncology, Middleton et al found that adding the multi–tyrosine kinase inhibitor vandetanib (Caprelsa) to gemcitabine did not improve overall survival in patients with previously untreated locally advanced or metastatic pancreatic carcinoma. Study ...
Japanese Phase II Trial of Nivolumab in Previously Treated Advanced Esophageal Cancer
In a Japanese phase II trial reported in The Lancet Oncology, Kudo et al found that nivolumab (Opdivo) had activity in heavily pretreated patients with advanced esophageal squamous cell carcinoma. Study Details In the study, with enrollment between February and November 2014, 65 patients...
Association of Metformin Use for Diabetes With Outcomes in HER2-Positive Breast Cancer
In an analysis from the phase III ALTTO trial reported in the Journal of Clinical Oncology, Sonnenblick et al found that among patients receiving adjuvant therapy for HER2-positive breast cancer, those with diabetes who received metformin had better outcomes than those who did not receive...
Dexamethasone Mouthwash in Preventing Everolimus-Related Stomatitis in Women With Breast Cancer
In the phase II SWISH study reported in The Lancet Oncology, Rugo et al found that use of a dexamethasone-based mouthwash may prevent everolimus-related stomatitis in postmenopausal women receiving everolimus (Afinitor) for hormone receptor–positive, HER2-negative metastatic breast cancer....
Thoracic 2017: SBRT Offers Curative Option for Patients With Lung Cancer Aged 80 and Older
Patients in their 80s and 90s who have early-stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to research presented by Cassidy et al at the 2017 Multidisciplinary Thoracic Cancers Symposium (Abstract...
Belgian Study Combines BRAF and MEK Inhibition in Advanced BRAF 600–Mutant Melanoma
In a Belgian two-center phase II trial reported in The Lancet Oncology, Schreuer et al found that rechallenge with the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) showed activity in patients with BRAF V600–mutant melanoma whose disease had progressed on...
Adding Temozolomide to Short-Course Radiotherapy in Older Patients With Glioblastoma
In a phase III trial reported in The New England Journal of Medicine, Perry et al found that adding temozolomide to short-course radiotherapy improved overall survival in patients aged ≥ 65 years with newly diagnosed glioblastoma. The survival advantage was largest among patients with methylated ...
Shraddha M. Dalwadi, MBA, on Stage I NSCLC: Racial Disparities in Treatment and Outcome
Shraddha M. Dalwadi, MBA, MD Candidate in the class of 2017 at Texas A&M Health Science Center, discusses findings from a SEER database study that showed African Americans and American Indians with stage I non–small cell lung cancer were less likely to receive definitive treatment and had lower ...
Richard J. Cassidy III, MD, on NSCLC and SBRT in Older Patients
Richard J. Cassidy III, MD, of Emory Winship Cancer Institute, discusses results from a multicenter analysis of stereotactic body radiotherapy for early-stage non-small cell lung cancer in patients 80 years and older; the patients tolerated the treatment well and had excellent estimated rates of...
Thoracic 2017: Racial Disparities Persist in Treatment and Survival of Early-Stage Lung Cancer
Analysis of the largest American cancer database indicates that racial disparities persist in the treatment and outcomes of patients diagnosed with stage I non–small cell lung cancer (NSCLC). Despite increased availability of potentially curative treatments for early-stage NSCLC,...
Thoracic 2017: Proton Therapy Offers New Treatment Possibility for Recurrent Lung Cancer
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment. In the largest analysis to date of reirradiation using intensity-modulated proton therapy for lung and other thoracic tumors, more than three-fourths of patients ...
Common Genetic Variation and Risk of Gallbladder Cancer in India
Several single-nucleotide polymorphisms in the chromosomal region containing both ABCB1 and ABCB4 genes were associated with an increased risk of gallbladder cancer, in an Indian case-control genome-wide association study reported in The Lancet Oncology by Mhatre et al. Study Details The study...
Thoracic 2017: Genetic Profile of Treatment-Resistant Lung Cancer More Variable Than Previously Thought
The genetic mutations underlying treatment resistance in non–small cell lung cancer (NSCLC) are more complex and dynamic than previously thought. Analysis of 355 biopsied tumors from patients who acquired resistance to epidermal growth factor receptor (EGFR) inhibitors, the most common form...
Thoracic 2017: Biomarker Test Shows Cancer Recurrence Months Before CT Scans
Results from a prospective clinical trial showed that a blood test looking at specific biomarkers was able to detect recurrences of lung cancer an average of 6 months before conventional imaging methods found evidence of recurrence. In the largest prospective clinical trial to date of circulating...
Association of DNA Thioguanine Nucleotide Concentration and Outcome During Maintenance Therapy for Childhood ALL
In a substudy of a European phase III trial (Nordic Society of Pediatric Hematology and Oncology ALL2008) reported in The Lancet Oncology, Nygaard Nielsen et al found that higher leukocyte DNA-incorporated thioguanine nucleotide (DNA-TGN) levels were associated with an improved relapse-free...
SGO 2017: Hospital Readmission Metrics May Not Be an Ideal Measure in Ovarian Cancer Cases
To reduce costs and improve quality of care, the Centers for Medicare & Medicaid Services (CMS) has made reducing hospital readmission rates a priority, yet two research studies presented at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer question the use...
SGO 2017: Secondary Endpoint Results of Phase III ENGOT-OV16/NOVA Trial of Niraparib in Recurrent Ovarian Cancer
Secondary endpoint results from the phase III ENGOT-OV16/NOVA trial of niraparib were presented at the 2017 Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, by Sven Mahner, MD, Director, Department of Gynecology and Obstetrics, University of Munich. “The results of...
FDA Approves Pembrolizumab for Relapsed or Refractory Classical Hodgkin Lymphoma in Adult and Pediatric Patients
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the treatment of adult and pediatric patients who have refractory classical Hodgkin lymphoma or have relapsed after three or more prior lines of...
Researchers Find Evidence-Based Radiation Treatment After Lumpectomy Leads to High-Quality, High-Value Care
A new study demonstrates that the use of less radiation therapy for patients with breast cancer who have undergone lumpectomy does not negatively impact patient outcomes, and could result in significant reductions in health-care costs. These findings, which examine patient eligibility for...
Busulfan and Melphalan vs Carboplatin, Etoposide, and Melphalan in High-Risk Neuroblastoma
In a phase III trial reported in The Lancet Oncology, Ladenstein et al found that high-dose chemotherapy with busulfan and melphalan vs carboplatin, etoposide, and melphalan was associated with an improved event-free survival in patients with high-risk neuroblastoma and adequate disease response to ...
Factors Associated With Early Death in Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Green et al found that risk factors for death within 1 month of diagnosis of childhood cancer included age up to 1 year, specific diagnoses, and minority race/ethnicity. The study involved analysis of data from SEER (Surveillance,...
Benefit of Imatinib in Chronic Myeloid Leukemia Persists Long Term in IRIS Trial
Long-term follow-up of patients with chronic myeloid leukemia (CML) randomized to imatinib in the IRIS trial was reported by Hochhaus et al in The New England Journal of Medicine. In the open-label crossover-design trial, 1,106 patients with CML were randomized to receive imatinib at 400 mg/d (n = ...
European Cohort Study of Vasectomy and Prostate Cancer Risk
In a large European cohort study reported in the Journal of Clinical Oncology, Smith Byrne et al found that vasectomy was not associated with an increased overall risk of prostate cancer or death from prostate cancer but appeared to increase the risk of lower-grade disease. Other studies have...
Binimetinib vs Dacarbazine: Which Was More Effective in NRAS-Mutant Melanoma?
In the phase III NEMO trial reported in The Lancet Oncology, Dummer et al found that treatment with the MEK inhibitor binimetinib improved progression-free survival vs dacarbazine in patients with advanced NRAS-mutant melanoma. Study Details In the open-label trial, 402 patients from 118 sites in ...
Blinatumomab vs Chemotherapy in Advanced Acute Lymphoblastic Leukemia
In the phase III TOWER trial reported in The New England Journal of Medicine, Kantarjian et al found that blinatumomab (Blincyto) treatment improved overall survival vs chemotherapy in heavily pretreated patients with B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab received...
ASCO Honors Researchers and Scientists for Significant Advancements in Cancer Treatment and Care
ASCO and the Conquer Cancer Foundation of ASCO (CCF) have proudly announced the winners of ASCO's Special Awards, the Society's highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders...
FDA Approves Ribociclib as Initial Therapy for Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
On March 13, 2017, the U.S. Food and Drug Administration (FDA) approved ribociclib (Kisqali), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor–positive,...
